Home / Transcripts / BioCryst Pharmaceuticals, Inc. (BCRX) · February 26, 2026

BioCryst Pharmaceuticals, Inc. (BCRX) Earnings Call Transcript

February 26, 2026

NASDAQ US Health Care Biotechnology earnings 42 min

Earnings Call Speaker Segments

Nick Wilder executive
#1

Hello, and thanks for joining us for BioCryst's conference call covering our corporate update for the full year 2025 along with our financial results. Here with me are our President and CEO, Charlie Gayer, our Chief Financial Officer, Anthony Doyle, and our Chief Development Officer, Dr. Bill Sheridan. You can find a press release and a slide presentation covering today's news on the investor relations section of our website. During this call, we might make forward-looking statements, such as statements about future results, unaudited and forward-looking financial information, and the company's future performance and or achievements. Known and unknown risks and uncertainties apply to these statements, and they could cause our actual results, performance, or achievements to differ materially from any future results or performance expressed or implied in this presentation. To learn more, including a detailed discussion of these risks, please see slide 2 of the presentation. Also, non-GAAP financial measures are part of today's conference call. To see a reconciliation of these non-GAAP financial measures against the most directly comparable GAAP financial measure, please see the earnings press release on the investor relations section of our website. I'll now hand the call over to Charlie.

Charlie Gayer executive
#2

Thank you. Appreciate it, Nick. So this marks my debut earnings call in the CEO seat at BioCryst, and I'm glad to share this update. I feel good about the position the company holds right now, and I'm even more enthusiastic about what lies ahead for us. We finished 2025 carrying solid momentum, posting ORLADEYO revenue for the full year of $601.8 million. That represents a 38% increase for the year, and 43% once you factor out the Europe business we divested in October. We're also kicking off 2026 positively, having broadened our HAE portfolio and completed our purchase of Astria Therapeutics last month. As I take on this new position, let me state plainly what BioCryst's strategy is: we are, and will stay, a profitable rare disease company, dedicated to addressing unmet patient needs via commercialization, innovation, and excellence, all grounded in well understood biology and disciplined clinical development. The area where we'll keep evolving is how focused and explicit we are regarding capital allocation and accountability. Our goal is to make sure each dollar we spend has a clear path to generating long-term value. Turning back to our HAE portfolio, we perceive enormous opportunity to create value by serving the needs of a rising number of HAE patients; our view is that HAE isn't a winner-take-all efficacy contest, but rather a structurally segmented market shaped by biology, patient preference, and real-world experience. Instead of a market that gets reset by each new entrant, we see one that segments according to what individual patients need. We currently hold a portfolio of differentiated products: ORLADEYO capsules for ages 12 and up, ORLADEYO Pellets for younger kids, plus a late-stage asset called navenibart. Every one of these therapies will let us capture growth and durable revenue within particular market segments. ORLADEYO has expanded robustly, partly due to its distinction as the oral choice. Even more crucially, there exists a super responder population able to achieve injectable-like attack control. Our pivotal trial showed that slightly more than 50% of patients who began ORLADEYO remained on it for two years and experienced a 91% reduction from baseline. In real-world use, 60% of patients continue therapy through 12 months, and close to 50% of all patients in the U.S. who have tried ORLADEYO across the past five years are still receiving therapy. The majority of ORLADEYO super responders probably won't switch, even if a different oral option hits the market, since their needs are already being met. Now we have a new addition to the ORLADEYO family; we're eager to introduce ORLADEYO Pellets for children ages 2 to under 12 at the AAAAI conference this weekend. The unmet need here is substantial, as HAE and related attacks go underdiagnosed among younger kids, and prophy usage is merely half that seen in adults. Having a safe, effective, and targeted oral prophy available could transform how children with HAE grow up, and ORLADEYO will likely stand as the sole oral option for several years ahead. When it comes to navenibart, we view it through the very same structural differentiation prism in HAE. Replacing ORLADEYO is not what navenibart is meant to do. What it's meant to do is let BioCryst serve patient needs throughout the entire spectrum of efficacy, dosing, and convenience preferences in HAE prophylaxis. Roughly 5,000 patients in the US inject somewhere between two times per week and once every four weeks and have excellent attack control. Because they're already well controlled, most of them don't want to gamble on an oral, and the injections themselves don't stand in the way of treatment. Oral isn't what they need. According to our research, a lot of them find the notion of an easy, highly efficacious injectable taken only 2 or 4 times a year very appealing... That's a jump patients who dose an injectable 12, 26, or even more than one hundred times a year will probably make, since it fits with what they're familiar with and delivers something superior. Keeping HAE prophylaxis treatment decisions inside the BioCryst portfolio is our aim; that's yet another way we consider long-term durability — not as protecting one product, but as owning the prophy decision framework in HAE. Three strong options will be offered by us, all coming from a team the HAE community knows and trusts. Before I hand things to Bill, I want to say a few words about BCX17725, our early-stage program in Netherton syndrome; it's a textbook rare disease story — a devastating genetic condition that goes underdiagnosed since no good treatment options exist. The results in healthy volunteers and the investigator enthusiasm for this program encourage us. By the end of the year, we're on a path to generate clinical data in patients, and that evidence, along with feedback from patients and investigators, will guide next steps. As we look ahead to 2026 and beyond, durable revenue growth is what we see, anchored by a skilled, motivated, and resilient commercialization team, serving adults and kids who want oral HAE prophylaxis. A second molecule advancing well in late-stage development that could lead the injectable prophylaxis segment, plus additional rare disease optionality in our pipeline, puts BioCryst in position for sustained value creation; with that, I'll turn it over to Bill to provide more color on our pipeline.

Bill Sheridan executive
#3

Appreciate that, Charlie. To kick things off, I'll walk through our HAE programs, and after that I'll give a quick update on where things stand with our Netherton syndrome program. So, starting with the navenibart pivotal phase III trial — recruitment is going really strongly, and the enthusiasm among investigators and people who might enroll as trial patients has been notable; we're looking at finishing enrollment of the 145 patients we need somewhere around the midpoint of 2026. For the ALPHA-ORBIT pivotal trial, the primary efficacy analysis is going to compare each navenibart dosing regimen against placebo, looking at the time-normalized rate of investigator-confirmed HAE attacks through 6 months. The phase II efficacy and safety profile we're presenting at AAAAI this weekend, coming out of the ALPHA-SOLAR trial, looks excellent — no safety signals across 29 patients through as much as 24 months of dosing, plus reductions from baseline in mean attack rates of 92% with dosing every three months and 90% with dosing every six months. Taken as a whole, the mean attack rate went from 2.23 per month at baseline down to 0.16 per month while on navenibart treatment. The median attack rate reduction came in at 97% for both dose regimens. Those results are outstanding. What these strong findings show is the durability, consistency, and quality of treatment responses with navenibart, and they give us a lot of confidence that the pivotal trial will succeed. Our expectation is that the pivotal trial results will confirm navenibart given every 3 months or every 6 months will establish a new standard in the field and be a very attractive option for HAE patients who are looking for injectable prophylactic therapies. Turning to the second item — we're thrilled that FDA approved our application for ORLADEYO oral pellets for children aged 2 to less than 12 in December 2025. At this point we're moving ahead with marketing authorization applications in other major regions, aiming to transform treatment choice for patients, parents, and children with HAE worldwide. Third, our clinical development program for BCX17725, our KLK5 inhibitor and Fc-fusion protein, in Netherton syndrome, has now entered patient-focused research. Parts 1 and 2 of our phase I trial in healthy volunteers, with single and multiple ascending doses, are complete. In those healthy volunteer cohorts, BCX17725 was given by subcutaneous and intravenous routes. Our investigational drug proved safe and was well tolerated. We saw no discontinuations, no dose-related adverse findings, and no safety signals. The highest dose given was 12 milligrams per kilogram every two weeks for three doses. As we mentioned on our last call, we were pleased to see evidence that the drug distributes to the epidermis. Drug exposure was roughly linear and proportional to dose, and the estimated half-life came in at about 12 to 19 days, which supports continued study of every two-week administration schedules. Today I'll give a refresher on the study design and an update on how things are progressing in the Netherton syndrome cohorts. Slide 18 outlines the study design. The patient cohorts in this study are open label and are designed to evaluate potential effects of the drug on clinical signs and symptoms of Netherton syndrome, along with safety and drug exposure. The study includes two groups of patients. The first is a short-term dosing group in Part 3, receiving treatment for 4 weeks. The second is a longer-term group in Part 4, dosed over 12 weeks. Certain sites got activated for Part 3 once short-term non-clinical safety studies had wrapped up, and later those same sites were activated for Part 4 after we finished longer-term non-clinical safety studies. Our focus is on enrolling patients into Part 4 first, since that gives us more extended dosing data, and we anticipate that 3 or fewer patients will go into Part 3. Our clinical investigators are enthusiastic about what this drug could do for Netherton syndrome and have already found patients who might qualify; we plan to enroll as many as 12 patients in Part 4 and have results ready by the close of this year. On the efficacy side, the main measure is the change from baseline in the Ichthyosis Area and Severity Index, or IASI score, while important secondary measures include the Investigator Global Assessment score and the Worst Itch Numerical Rating Scale score, plus we'll look at quality of life metrics as well. We plan to choose doses and endpoints for a pivotal trial based on findings from this phase I trial. At this point I'll hand the call over to Babar for the financial review.

Babar Ghias executive
#4

Thank you, Bill. The past twelve months marked a pivotal period for our organization. We achieved robust revenue expansion, profitability at an all-time high, and further solidified our already-strong balance sheet; those outcomes were not merely digits; they demonstrated that our approach is effective and that our operating framework was designed to handle growth. Before discussing the financial details, I'd like to emphasize that we are offering greater transparency in our financials so that the underlying strength of our core business can be better appreciated. For our GAAP financial metrics, please see the press release issued today. In my comments, I will reference non-GAAP numbers, which have been adjusted to account for the divestiture of the European ORLADEYO business, stock-based compensation, costs tied to workforce reductions, and expenses related to transactions. We hold the view that non-GAAP figures offer a more transparent picture of the business looking forward. Our non-GAAP total revenue for 2025 rose 45% compared with the prior year. Because other revenues contain a contribution from RAPIVAB, which sits outside our core operations, I'd direct your focus to non-GAAP ORLADEYO revenues, which grew by roughly $169 million, or 43%, versus the previous year. This stemmed from outstanding daily execution by our commercial team throughout 2025. By capitalizing on our best-in-class real-world evidence generation strengths, we effectively boosted patient volume and achieved meaningful headway on paid shipments. We have already begun to observe how the European divestiture affects our operating performance in Q4. Our non-GAAP operating profit climbed to $214 million, up 198% compared with the prior year — the highest level ever recorded in BioCryst's history. R&D costs declined modestly in 2025 as we advanced key programs while concluding certain others and restructuring the team; we expect that 2026 R&D costs will rise relative to 2025 as we finish the ongoing phase III trial and BLA-enabling CMC activities for navenibart. Once these efforts are finished, development costs will naturally decrease after 2026; we will stay intensely focused on preserving discipline in R&D spending and directing capital toward opportunities with high ROI. In that same vein, any programs lacking a compelling path forward will be terminated promptly. Our sales and marketing expenses for the year totaled $144 million on a non-GAAP basis, having risen mainly because of certain reallocation methodology, pre-launch costs for pediatrics, and increased specialty distribution fees and incentive comps, which naturally resulted from the strong top-line growth. As you can work out, for each dollar put into our sales and marketing engine, we produced a return of roughly four times on ORLADEYO net sales. Although we do expect some modest incremental annual expense connected to top-line growth, the ROI on ORLADEYO will keep expanding as we push the business toward its blockbuster potential. If we look ahead to a possible approval of navenibart, the sales and marketing expense backing our HAE franchise overall will be highly stable, predictable, and offer even greater ROI upside. We've assembled a rare disease commercial operation that ranks among the strongest in this sector — an infrastructure with real scalability that positions us to pull off several successful launches down the road, both in HAE and other areas, whether that means a different asset from our own pipeline or one we bring in through acquisition or licensing. Thanks to how well we performed operationally, we closed out the year sitting on a powerful liquidity cushion: $337.5 million held in cash and investments. At the same time we completed the Astria acquisition, we arranged a very favorable $400 million financing package with Blackstone Life Sciences — a financial ally whose growth vision matches ours. Given this continuing momentum, plus the new advantage that over the upcoming two years we can draw on our prior period tax NOLs, our cash flow generation stands to be quite robust. That gives us flexibility to weigh a broad range of capital allocation approaches that support lasting value creation — whether that's M&A, paying down debt, or repurchasing shares. Now to guidance. For full-year 2026, we're holding our ORLADEYO revenue expectation at somewhere between $625 million and $645 million, and the midpoint works out to roughly 13% growth versus 2025 revenues adjusted for Europe. For full-year 2026, non-GAAP OpEx should land somewhere between $450 million and $470 million, a figure that now accounts for Astria expenses, consistent with what we guided previously. As Charlie stressed, our confidence remains high that ORLADEYO stands on firm ground to reach blockbuster potential. Patient growth keeps coming, powered by the trends we walked through earlier along with the recent pediatric approval, which will play a meaningful role in that growth. Having flipped this profitability card in 2025, we're firmly dedicated to remaining profitable and to furthering cash flow generation moving ahead. In summary, looking back at 2025, the strength we showed during that year clearly amounts to more than just a financial milestone. It serves as a springboard toward what lies ahead. We head into 2026 carrying momentum, a sharper competitive edge, and the discipline to make sure each investment we undertake drives value creation. Our aim is to keep pushing our pipeline forward via organic innovation as well as selective, disciplined BD capable of broadening our capabilities and speeding up our impact within rare disease. We're thrilled to continue constructing BioCryst's next growth phase — a company that doesn't merely deliver quarter after quarter, but compounds value across the long term as we carry out that vision. Operator, we're ready now for your questions.

Laura Chico analyst
#5

Morning, everyone, and thanks for taking my question. I'd like to begin with navenibart. Could you provide a bit more detail on the timeline for the regulatory submission by year-end 2027? Is it still assumed that phase III data will arrive by early 2027? I just want to understand the steps that need to happen between top-line data and submission. On a related note, you brought up the AAAAI late breaker. How should we view that in relation to ALPHA-STAR? It looks quite consistent when it comes to the attack rate reductions. I'm curious whether there are incremental learnings here around perhaps the attack-free period. Thanks very much.

Charlie Gayer executive
#6

Thanks, Laura; yes, we're obviously very excited about navenibart. Yes, everything remains on track for filing, such that we would be on track to file by the end of next year, and therefore on track for approval by late 2028. Bill, would you like to address the question about the regulatory process?

Bill Sheridan executive
#7

Sure.

Charlie Gayer executive
#8

Next steps.

Bill Sheridan executive
#9

As with other preventive treatments for HAE, this is a chronic condition, so you need 12 months. You require 12 months of safety data; that will come in mid-2027, and that is truly what determines when the BLA submission happens. What was the last question?

Charlie Gayer executive
#10

Last thing — just the data. Yes, we couldn't be more thrilled about it. That 92% decrease, the average drop for the 3-month dose, and 90% for the 6-month dose really demonstrate remarkable consistency. Another thing I'd say matters a great deal is the mean attack rate of 0.16 throughout the population starting from their baseline. That works out to fewer than two attacks annually for patients. And on top of that, the intensity of those attacks declined too. During the majority of the year, patients are essentially free of attacks, and that's exactly what they want.

Laura Chico analyst
#11

I really appreciate it. I'm going to get back in line.

Brian Abrahams analyst
#12

Hello, and good morning, everyone. Thank you for fielding my questions. Congratulations on the ongoing impressive momentum. You mentioned the ORLADEYO super responders a bit — those who remain on treatment, you know, with solid persistence across extended stretches. So I suppose, do you have any idea how one might forecast who will turn out to be a super responder? Maybe in that same vein, I'm wondering how you picture placing navenibart within that setting — meaning, do you encourage patients to move over to ORLADEYO, and afterward, should they fail to respond, you know, navenibart might become a choice for them, or instead would you mainly be positioning navenibart for that group of 5,000 patients who are doing well on injectables and could benefit from something dosed less often? And perhaps walk us through a few elements of the navenibart profile once more — specifically how many injections, anti-drug antibodies, refrigeration needs, plus anything else that must be addressed regarding formulation prior to commercialization. Thanks.

Charlie Gayer executive
#13

Okay, thank you. Appreciate it, Brian. I’ll kick things off, and then Bill will also address a few of those questions. When it comes to forecasting which patients will be super responders to ORLADEYO, honestly, the only way to find out is for patients to give it a try. For one thing, a patient has to actually want an oral option, and we’re aware that most patients do prefer an oral. Looking across all our clinical data — the various factors like age, sex, weight, prior prophylaxis history, and so on — nothing allows us to anticipate who will respond. As we understand it, HAE attacks are frequently triggered by stress and other life circumstances. Our approach, I think, is to encourage patients who have interest in an oral therapy to try it. The majority of them do very well. We’d like them to undergo a trial lasting 3 to 6 months to truly determine whether this drug suits them. What we observe is that by the one-year mark, roughly 60% of them conclude it is the right drug for them. Regarding how navenibart is positioned relative to ORLADEYO, the main opportunity we see for navenibart is among those 5,000 patients currently on injectables. As I mentioned in my remarks, those patients remain on injectables because they’re doing well, but some of them, you know, are injecting 100+ times a year. Being able to offer just 2 to 4 injections, we believe, will be really compelling, and that’s what our patient research shows. ORLADEYO, then, will be for patients who wish to begin prophylaxis with an oral. It will be the established, trusted choice backed by many years of data and experience. ORLADEYO is for anyone who wants oral. navenibart is for those who want an even better injectable positioning. For patients who try ORLADEYO and find it isn’t the drug for them, that too represents an opportunity for navenibart, all within the same BioCryst portfolio. With navenibart, the number of injections will actually be quite straightforward. It will launch with an auto-injector and the 3-month dose following a 600 mg loading dose, which will be 2 injections, 2-milliliter injections. The 3-month dose is then one injection. The 6-month dose is 2 injections. Very simple. Bill, there was also a question about ADAs and.

Bill Sheridan executive
#14

Yeah.

Charlie Gayer executive
#15

Other things that...

Bill Sheridan executive
#16

Prior to diving into that, regarding the ability to predict things, I want to underscore what Charlie mentioned. Until you actually try ORLADEYO, you won't know if you'll turn out to be a super responder. It provides benefits for patients across every HAE category. Beyond age, sex, race, weight, and prior Prophy exposure, you can also include whether someone's attack rate is high or low, whether attacks are less or more predictable, and whether they have type one or type two HAE or C1 inhibitor, normal HAE — every one of those categories sees a benefit, and we've demonstrated that very conclusively through both our clinical trials and our real-world evidence studies. You also brought up the maturity of the formulation development program for navenibart. That's entirely finished; it's quite mature. CMC is in an excellent position.

Charlie Gayer executive
#17

I've just got one question regarding ADAs.

Bill Sheridan executive
#18

When it comes to ADAs, nothing suggests they have any effect on efficacy based on what we saw in phase II. Naturally, as with any biologic, this is something you address within the development program. You build assays and screen for ADAs. They always show up, and the real question is whether patients keep getting benefit from the drug. Up to now, that's precisely what we're seeing. Neither safety nor efficacy appears to be affected by ADAs.

Charlie Gayer executive
#19

As a quick reminder for everyone, the information we're sharing during this weekend's session relates to individuals receiving navenibart, with follow-up extending to 24 months.

Bill Sheridan executive
#20

Yeah.

Charlie Gayer executive
#21

With a mean of about 12 months.

Bill Sheridan executive
#22

One last thing about the injections, they don't hurt.

Charlie Gayer executive
#23

Charlie Gayer here.

Brian Abrahams analyst
#24

Brian Abrahams speaking—that does indeed help a lot. Bill, Charlie, I truly appreciate it, both of you.

Bill Sheridan executive
#25

Thank you, Brian.

Mikaela Vanik analyst
#26

Hello, I'm Mikaela Vanik, filling in for Steve. Regarding Netherton, we're hoping you could clear something up: will parts 3 and 4 data come out simultaneously? In addition, could you address how severe the disease is and how much it varies from patient to patient at baseline? Would you expect that enrolling a mixed group of patients—or, I should say, a more homogeneous set—would be hard to do? Also, which prior therapies are permitted, and how do patients move forward depending on their particular disease phenotype? Thanks so much.

Charlie Gayer executive
#27

All right. Let me begin with parts 3 and 4. Bill is able to speak to the severity of disease and the kinds of patients. We intend to put out every piece of data at once. We expect just a couple or a few individuals in part 3—perhaps two or three. As Bill mentioned, all our locations are now ready to move ahead into part 4, and in our view, that three-month dosing schedule is the piece that will truly matter. Rather than enrolling a single person at a time, our intention is to put out a full data set. Bill, go ahead and describe the patients.

Bill Sheridan executive
#28

Absolutely—when it comes to how severe cases can be, Netherton syndrome definitely has a range. What our studies on how common the condition is are showing us, as Charlie mentioned, is that it’s underdiagnosed, and that’s likely due in large part to the fact that no therapies have been approved, but also because patients differ in how severely they’re affected. The individuals we’ve encountered who have this condition show clear, very clear signs of disease, and they’ve developed ways to cope, and, you know, their lives have been profoundly affected. That aspect doesn’t concern me when it comes to enrolling participants. You know, the investigators we’re working with who are preparing their patients are actually more concerned about securing slots for those patients in the study than about having too few patients to enroll. As for eligibility, yes, we do require proof of disease so we can determine if the drug provides any benefit. That’s what we’re doing; we’re choosing patients who clearly have the condition. You know, I think, I think it’ll, I think it’ll work out. That’s not something I’m worried about.

Mikaela Vanik analyst
#29

All right. Thanks for that.

Analyst analyst
#30

Hey there, Amy here, filling in for Maury, and nice work on the quarter. This is a quick follow-up to something asked earlier. Could you share additional details about the way you'd give updates and disclosure regarding the navenibart program? Would you discuss your approach for perhaps getting the FDA to speed up the timelines? Thanks so much.

Charlie Gayer executive
#31

Absolutely. Regarding navenibart, like Bill said, enrollment is going well, and we'd likely give an update at the point when the pivotal study has everyone enrolled; then, what did you ask after that?

Bill Sheridan executive
#32

The second part is about doing our best to pull that forward...

Charlie Gayer executive
#33

Yeah.

Bill Sheridan executive
#34

as this program matures.

Charlie Gayer executive
#35

That is clearly a priority for us. Take, for instance, the sections of the BLA we are able to begin drafting — we will begin drafting them. We will not have a completely precise picture regarding the BLA timeline until a pair of things occur: first, the final patient's initial visit, which lets us project when that patient's final visit will be, 12 months afterward, clearly. Second, obtaining alignment with the division during a pre-BLA meeting concerning the full contents of the BLA — that, obviously, happens afterward. I believe we can offer greater clarity before long.

Analyst analyst
#36

Thanks.

Analyst analyst
#37

Hello, Catherine here, filling in for Jon. I've got one brief thing to ask regarding whether any effects are showing up from the fairly recent newcomers, oral acute treatments included. Is it the case that some patients are moving over to ORLADEYO, or do the motives behind patient switches look different in some way? I realize revenues haven't really taken much of a hit, but if you're anticipating some effect, or if it's beginning to appear at all, any detail would help. Thanks.

Charlie Gayer executive
#38

Absolutely, Catherine. As we've stated, especially quite frequently during the prior year, ahead of newcomers arriving, our expectation was no impact on ORLADEYO from new prophy competitors, since there's a genuine distinction between those wanting an oral prophy and those who feel more at ease with injectables. Our expectation was that injectables would mainly fight it out with the injectables already out there, and that's precisely what we observe; prescribing habits for ORLADEYO and patient habits generally aren't shifting. When it comes to oral, on-demand oral acute therapy, that is definitely something we observe. It isn't harming ORLADEYO in any respect; our view is that with time, a possible tailwind could emerge simply from patients wanting an all-oral combo, meaning a single pill taken once daily for attack prevention, then for the sporadic breakthrough attacks, another oral as treatment. That represents a wonderful chance for a lot of patients, though it's premature to determine if such a tailwind will materialize.

Analyst analyst
#39

Many thanks.

Analyst analyst
#40

Hello, and good morning. John here, filling in for Serge today. We appreciate you taking our questions. To start, regarding ORLADEYO: you raised the price by 9% back in January. Apart from that, I'm wondering which factors you'll focus on most intently during 2026 — keeping up the pace of new patients added, or achieving modest gains in paid prescription rates, whether through Medicare or commercial channels. Then, about the pellet formulation for pediatric use, how should we think about the timing of identifying and converting patients across 2026? Also, does the guidance you've issued now factor in any meaningful contribution from that segment during this year?

Charlie Gayer executive
#41

Great. Thanks. Appreciate that, John. So in early January we put through a price hike of 9%, and that's bigger than our past increases. After rebates and discounts, we'll keep around half, so about 4.5% net. The main reason is that ORLADEYO was priced well below where most competing products sit, so this was mostly about closing that gap, and we won't need increases of that size down the road to get to our $1 billion peak; as far as this year goes, the metric we care about most is growth in net patients. During today's presentation, we mentioned that reaching $1 billion by 2029 requires an average net gain of 150 patients annually across this year plus the following three. That $1 billion target is very close at hand — it's our top priority. Naturally, we're continuously striving to nudge the paid rate upward bit by bit. Last year brought a substantial increase on that front, and from here it's simply a matter of steady, incremental gains, which we support through our real-world evidence. In patients with normal C1 inhibitor, for example, a growing number of plans are beginning to establish favorable coverage policies, thanks to the real-world evidence we supply — an ongoing effort. Regarding the pellets, I noted during my comments that HAE often goes undiagnosed among children. In claims data, we identified roughly 500 pediatric patients below 12 years old, yet according to epidemiology statistics, approximately 1,200 ought to exist. Part of the explanation is that moms and dads may hesitate to have their children screened, since they honestly wish their child won't turn out to have HAE. However, we believe that once an oral treatment becomes available — something witnessed during the HAE market's early stages — the presence of a therapy drives diagnosis. That represents a chance for market expansion. Additionally, only around 40% of children receive prophylactic treatment, which is half the rate seen in adults. You could see the count of children who get diagnosed possibly as much as twice what it is now, and the share receiving treatment could also reach twice today's level. An oral prophy, in our view, is the right approach to make that happen. As for the guidance we've given, the pellets and pedes launch is indeed baked into what we're projecting for this year, but it's a pretty small piece of it. Looking further out, we're quite bullish on what this indication will mean both for kids and for the top line. The open question is how quickly that change takes hold; we've taken a conservative stance in our assumptions for this year and plan to watch how it plays out. If it, well, moves ahead more rapidly than anticipated, that could provide a favorable boost.

Analyst analyst
#42

Hello, everyone. Vish here, filling in for Stacy. Congrats on an excellent year, and I truly value what you shared regarding competitive dynamics. Thank you for fielding our questions. We've got two. To start, regarding ORLADEYO projections for Q1, could you help us understand how the reauthorization process is shaping up this year? We're aware that you achieved certain enhancements to that process during the previous year, and those enhancements led to reauthorizations happening more quickly than anticipated. Please just take us through what you're observing and what we along with investors ought to anticipate for Q1. And then, second, which is our last one, considering the sale of the EU business, would you be open to breaking down your 2026 guidance for us between US and ex-US contributions? What's the right way for us to think about that?

Charlie Gayer executive
#43

Thanks so much, Vish. I'll handle the first one, and then hand things to Babar for the second. Q1 — each Q1 represents the major reauthorization period. It involves an enormous amount of effort. Our team gets ready for it; they are currently deep in that work, and our team has become highly skilled at it. Here's what to anticipate for Q1: since this year we lack any massive tailwind comparable to what we enjoyed last year from the Medicare patients and the Affordable Care Act — making, the IRA, making things more affordable for patients. The Medicare patients are doing very well, but we won't have that tailwind; this year, expect revenue likely to decline somewhat compared to Q4 while we work through the reauth; we must provide more free product, we must cover a greater share of co-pays for commercial patients. That reduces revenue even while our patient base keeps expanding. A slight decrease in Q1, followed by a rebound in Q2. Babar, do you want to address U.S. versus global?

Babar Ghias executive
#44

Yeah, absolutely. Regarding what you asked about expenses and what Europe brings in, if you check the financial tables in our press release, we did try to separate out that entire European operation. As we've said before, that European business was growing, but it was also losing money. You can see our base business margins were extremely strong relative to the U.S. business margins, which are extremely strong relative to Europe. When you look at that profitability figure I mentioned, $214 million, all of Europe is taken out of it. From the exhibits, you can figure out that base business costs come to roughly $380 million for the U.S. in 2025. To put it in perspective, what it looks like in 2026 — and this ties back to that same cost discipline — we got rid of Europe, but we brought in a very, very highly de-risked late-stage program in navenibart. Our total costs fall in the $450-$470 range, and the base business really isn't growing by much within that. The added costs mostly come from bringing in Astria; that's the discipline I mentioned, that we'll keep making sure our base business costs stay low while we keep driving growth. Hope that answers your question.

Analyst analyst
#45

Yeah. Apologies, and thanks for making that clear, Babar. What I asked about concerned the 2026 guidance — the $625 million-$645 million figure we're anticipating for this year. In terms of the U.S. versus ex-U.S. breakdown, how are we supposed to look at that?

Babar Ghias executive
#46

Yeah, the bulk of it will come from the U.S; we have

Analyst analyst
#47

Alright.

Babar Ghias executive
#48

So looking at how things break down across some markets, as you can see, following Europe, that's typically where the split falls. At this point it sits just above 90%, so while we aren't providing a detailed breakout, most of that share is, you know, generated by the U.S. business.

Analyst analyst
#49

Understood. Many thanks.

Charlie Gayer executive
#50

Thank you, appreciate it a lot. As we have been explaining, 2026 is an extremely significant year for BioCryst. ORLADEYO patient growth keeps going. The launch of ORLADEYO for kids has us very excited. There is a lot of important clinical trial work being carried out for navenibart in BCX17725, and that effort is progressing well. I truly want to express my gratitude to every hardworking owner at BioCryst for their efforts in making 2025 such a strong year, and for what they are doing in this one to produce yet another year of outstanding results. Thank you, all. Enjoy the rest of your day.

Operator operator
#51

That brings us to the end of this call. We appreciate your joining us for today's presentation. You're welcome to log off at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete BioCryst Pharmaceuticals, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to BioCryst Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.